community-acquired pneumonia


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to community-acquired pneumonia: Nosocomial pneumonia

community-acquired pneumonia (CAP),

pneumonia caused by any organism found regularly outside the hospital; common organisms include Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma, as opposed to hospital-acquired or nosocomical pneumonia.

community-acquired pneumonia

(kə-myo͞o′nĭ-tē-)
n.
Pneumonia that a person acquires outside of a hospital or other health care institution, as distinguished from nosocomial, or hospital-acquired pneumonia.

community-acquired pneumonia

Pneumonia caused by an infection currently present in the community; CAP is the most common cause of infectious death–US, and number 6 killer overall; of the 57% of CAPs in which a pathogen is identified, S pneumoniae causes 60%, H influenzae 15%, Legionella pneumophila 10-15%, Staphylococcus aureus 2-10% Clinical Atypical pneumonia with delayed recognition; early SX are distinctly nonpulmonary–eg, dry cough, myalgia, arthralgia Diagnosis Pathogens in pleural fluid or blood cultures, Pneumocystis carinii in sputum or BAL, a 4-fold ↑ in Mycoplasma pneumoniae antibody titers, isolation of L pneumophila, or a 4-fold ↑ in L pneumophila antibody titers, or positive direct fluorescent antibody test for legionella, S pneumoniae antigen in serum, urine Risk factors Alcoholism, seizure disorders, smoking, immunosuppression

community-acquired pneumonia

Pneumonia occurring in outpatients, often caused by infection with streptococcus, Haemophilus influenzae, Staphylococcus aureus, and atypical organisms such as Legionella species. Mortality is approximately 15% but depends on many host and pathogen features.
See also: pneumonia
References in periodicals archive ?
Incidence and characteristics of viral community-acquired pneumonia in adults.
TB presenting as community-acquired pneumonia in a setting of high TB incidence and high HIV prevalence.
Because there are few drugs in late-stage development for the indication, ceftaroline has the potential to be an important therapeutic option for patients hospitalized with community-acquired pneumonia.
We forecast that these two agents combined will earn nearly $100 million in the community-acquired pneumonia market in 2018.
We are extremely encouraged by the positive results we've seen in this Phase 2 trial of radezolid in community-acquired pneumonia," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals.
All patients were 18 years old or older, all had received a chest x-ray within 24 hours of admission, and all had a diagnosis consistent with community-acquired pneumonia, wrote Dr.
The new report entitled Hospital Anti-Infectives Insight Series: Community-Acquired Pneumonia also finds that future therapies modeled after Johnson & Johnson/Basilea's ceftobiprole or Forest/Novexel's ceftaroline could be used as empiric first-line therapies for very severe cases of community-acquired pneumonia requiring admission to the ICU or mechanical ventilation.
SAN FRANCISCO -- Patients with HIV do just as well as patients without the virus when faced with bacterial community-acquired pneumonia, according to a poster presentation by Dr.
Community-acquired pneumonia is one of the leading causes of hospitalization in the United States and the most common cause of death in patients with infectious diseases (2), while acute otitis media is the most frequent illness for which antimicrobial drugs are prescribed for children in the industrialized world.
FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity.
April 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a therapy's overall clinical efficacy (defined as cure or improvement of symptoms) is the attribute that most influences primary care physicians' prescribing decisions for community-acquired pneumonia.
MONTREAL -- New guidelines for the management of community-acquired pneumonia provide an excellent framework for site-of-care decisions, but they must be augmented with a good dose of clinical judgment, according to Glenn Tillotson, Ph.

Full browser ?